Regional differences in outcomes with ablation versus drug therapy for atrial fibrillation: Results from the CABANA trial

• Published in: The American heart journal 2024-04, Vol.270, p.103-116
• Main Authors: Cappato, Riccardo, Mark, Daniel B., Silverstein, Adam P., Noseworthy, Peter A., Bonitta, Gianluca, Poole, Jeanne E., Piccini, Jonathan P., Bahnson, Tristram D., Daniels, Melanie R., Al-Khalidi, Hussein R., Lee, Kerry L., Packer, Douglas L.
• Format: Article
• Language: English
• Subjects: Ablation; Antiarrhythmics; Anticoagulants; Cardiac arrest; Cardiac arrhythmia; Cardiovascular disease; Catheters; Clinical trials; Comorbidity; Coronary vessels; Death; Drug therapy; Effectiveness; Enrollments; Fibrillation; Geographical variations; Heart failure; Hypertension; Hypotheses; Medical instruments; Mortality; Patients; Regional differences; Regions; Statistical analysis; Stroke; Vein & artery diseases
• ISSN: 0002-8703; 1097-6744; 1097-6744
• DOI: 10.1016/j.ahj.2024.01.009

The finding of unexpected variations in treatment benefits by geographic region in international clinical trials raises complex questions about the interpretation and generalizability of trial findings. We observed such geographical variations in outcome and in the effectiveness of atrial fibrillation (AF) ablation versus drug therapy in the Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial. This paper describes these differences and investigates potential causes. The examination of treatment effects by geographic region was a prespecified analysis. CABANA enrolled patients from 10 countries, with 1,285 patients at 85 North American (NA) sites and 919 at 41 non-NA sites. The primary endpoint was a composite of death, disabling stroke, serious bleeding, or cardiac arrest. Death and first atrial fibrillation recurrence were secondary endpoints. At least 1 primary endpoint event occurred in 157 patients (12.2%) from NA and 33 (3.6%) from non-NA sites over a median 54.9 and 40.5 months of follow-up, respectively (NA/non-NA adjusted hazard ratio (HR) 2.18, 95% confidence interval (CI) 1.48-3.21, P < .001). In NA patients, 78 events occurred in the ablation and 79 in the drug arm, (HR 0.91, 95% CI 0.66, 1.24) while 11 and 22 events occurred in non-NA patients (HR 0.51, 95% CI 0.25,1.05, interaction P = .154). Death occurred in 53 ablation and 51 drug therapy patients in the NA group (HR 0.96, 95% CI 0.65,1.42) and in 5 ablation and 16 drug therapy patients in the non-NA group (HR 0.32, 95% CI 0.12,0.86, interaction P = .044). Adjusting for baseline regional differences or prognostic risk variables did not account for the regional differences in treatment effects. Atrial fibrillation recurrence was reduced by ablation in both regions (NA: HR 0.54, 95% CI 0.46, 0.63; non-NA: HR 0.44, 95% CI 0.30, 0.64, interaction P = .322). In CABANA, primary outcome events occurred significantly more often in the NA group but assignment to ablation significantly reduced all-cause mortality in the non-NA group only. These differences were not explained by regional variations in procedure effectiveness, safety, or patient characteristics. ClinicalTrials.gov Identifier: NCT0091150; https://clinicaltrials.gov/study/NCT00911508